Diuretics: pharmacological basis of clinical effects

Regulation of water-salt metabolism is complex and is determined by many factors. Diuretics have affinity for renal tissue and limit the reabsorption of sodium ions in the nephron and secondarily reduce the reabsorption and secretion of other ions and water.

Classifications of diuretics are given, the mechanisms of their action are considered, and the main indications for use are listed, taking into are indicated, taking into account the newly discovered mechanisms, contraindications and side effects are listed. Attention is focused on the use of drugs of other groups that have a diuretic effect. Gliflozins - blockers of sodium-glucose cotransporter-2 type, are promising drugs for overcoming resistance to diuretics. Vaptans inhibit membrane aquaporin transporter proteins (AQPs), are coupled to vasopressin receptors, and reduce water reabsorption in collecting tubules without affecting natriuresis. Vasopressin receptor blockade accelerates the elimination of fluid from the body and improves the symptoms and signs of CHF with short-term use. The diuretic effect can be caused by lithium by a sharp decrease in AQP-2 in the apical membrane of the collecting tubules. Screening of new diuretics involves further study of pendrin inhibitors as monotherapy and in combination with known diuretics. Screening of new diuretics involves further study of pendrin inhibitors in the form of monotherapy and in combination with known diuretics. Prospects for the development of diuretics are outlined.

In modern practice, both classical diuretics and new drugs with an additional diuretic effect and a number of pleiotropic properties, including cardio- and nephroprotection, are used. The action of classical diuretics is not limited to the diuretic effect. They have been proven to improve the prognosis in patients with chronic heart failure and chronic kidney disease, form the basis for the treatment of ascites in cirrhosis of the liver, facilitate the achievement of target blood pressure values and reduce cardiovascular risks as part of combination therapy, and are effective in glaucoma.

1. Golan D. E., Armstrong E. J., Armstrong A. W. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy: Fourth Edition, 2017. 1042 p.

2. Kehrenberg M. C. A., Bachmann H. S. Diuretics: a contemporary pharmacological classification? Naunyn-Schmiedeberg’s Arch Pharmacol. 2022;(395):619–627. https://doi.org/10.1007/s00210022-02228-0.

3. Mironov S. E., Gorbunov A. A., Tihonov D. A., Lemina E. Ju. Principy dejstvija mochegonnyh sredstv. Jeksperimental’naja i klinicheskaja farmakologija. 2022;85(8):40–48 (In Russ.).

4. Maksimov M. L., Ermolaeva A. S., Kuchaeva A. V. Vybor preparata dlja diureticheskoj terapii: vzgljad klinicheskogo farmakologa. RMZh. 2018;1(2):115–119. (In Russ.).

5. Huxel C., Raja A., Ollivierre-Lawrence M. D. Loop Diuretics. [Updated 2022 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-20.

6. Gurevich M. A. Petlevoj diuretik torasemid - mehanizmy dejstvija, klinicheskoe ispol’zovanie pri neoslozhnennoj forme arterial’noj gipertonii. Trudnyj pacient. 2018;16(7):17–19. (In Russ.).

7. Akbari P., Khorasani-Zadeh A. Thiazide Diuretics. StatPearls. Treasure Island (FL): 2022.

8. Jo W., Koh E. S., Chung S. Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease. Clinical Hypertension. 2023;(29):14. https://doi.org/10.1186/s40885-023-00238-5.

9. Alshahrani S., Rapoport R. M., Zahedi K. et al. The non-diuretic hypotensive effects of thiazides are enhanced during volume depletion states. PLoS ONE. 2017;12(7):e0181376. https://doi.org/10.1371/journal.pone.0181376.

10. Nechesova T. A. Hlortalidon v sovremennyh rekomendacijah po lecheniju arterial’noj gipertenzii. Kardiologija v Belarussii. 2021;13(3):486–492. (In Russ.). ISSN: 2072-912XeISSN:2414-2131.

11. Arterial’naja gipertenzija u vzroslyh. Klinicheskie rekomendacii. Rossiĭskiĭ kardiologicheskiĭ zhurnal. 2024;29(9):6117. (In Russ.). https://doi.org/10.15829/1560-4071-2024-6117.

12. Kochetkov A. I., Ostroumova O. D. Klinicheskoe znachenie organoprotektivnyh svojstv antigipertenzivnyh preparatov v novyh rekomendacijah po arterial’noj gipertonii: vozmozhnosti antagonistov kal’cija i diuretikov. Consilium Medicum. 2019;21(5):11–18. (In Russ.). https://doi.org/10.26442/20751753.2019.5.190417.

13. Ștefănescu B. E., Szabo K., Mocan A., Crişan G. Phenolic Compounds from Five Ericaceae Species Leaves and Their Related Bioavailability and Health Benefits. Molecules. 2019;24(11):2046. https://doi.org/10.3390/molecules24112046.

14. Wojnicz D., Kucharska A.Z., Sokół-Łętowska A. et al. Medicinal plants extracts affect virulence factors expression and biofilm formation by the uropathogenic Escherichia coli. Urol Res. 2012;40(6):683–97. https://doi.org/10.1007/s00240-012-0499-6.

15. Major H. Untersuchungen zur Wirkungsweise von Birkenblättern (Betulae folium) und phenolischer Verbindungen. Berlin, 2002.139 p.

16. Rastogi S., Pandey M. M., Rawat A. K. S. Medicinal plants of the genus Betula — Traditional uses and a phytochemical–pharmacological review. Journal of ethnopharmacology. 2015;159:62–83.

17. Afshar K., Fleischmann N., Schmiemann G. et al. Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) – a double-blind, randomized, controlled comparative effectiveness trial. BMC Complement Altern Med. 2018;18(1):203. https://doi.org/10.1186/s12906-018-2266-x.

18. Rozhdestvenskij D. A., Bokij V. A. Klinicheskaja farmakologija proantocianidinov kljukvy: sovremennyj vzgljad na terapiju infekcij mochevyh putej. Mezhdunarodnye obzory: klinicheskaja praktika i zdorov’e. 2014;(4):149–159. (In Russ.).

19. Kowalska K. Lingonberry (Vaccinium vitis-idaea L.) Fruit as a Source of Bioactive Compounds with Health-Promoting Effects. A Review. Int J Mol Sci. 2021;22(10):5126. https://doi.org/10.3390/ijms22105126.

20. Vilkickyte G., Petrikaite V., Pukalskas A. et al. Exploring Vaccinium vitis-idaea L. as a potential source of therapeutic agents: antimicrobial, antioxidant, and anti-inflammatory activities of extracts and fractions. J. Ethnopharmacol. 2022;(292):115207. https://doi.org/10.1016/j.jep.2022.115207.

21. Lameire N. Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure. Kidney Dial. 2023;3:56–72. https://doi.org/10.3390/kidneydial3010005.

22. Batjushin M. M. Primenenie ingibitorov natrij-gljukoznogo kotransportera 2 tipa pri hronicheskoj serdechnoj nedostatochnosti i hronicheskoj bolezni pochek. Rol’ jempagliflozina. Rossijskij kardiologicheskij zhurnal. 2021;26(1S):4349. (In Russ.). https://doi.org/10.15829/1560-4071-2021-4349.

23. Shhepareva M. E., Zaharova M. N. Rol’ akvaporinov v funkcionirovanii nervnoj sistemy v norme i pri patologii. Nejrohimija. 2020;37(1):5–14. (In Russ.).

24. Bizunok N. A., Gajduk A. V. Mochegonnye sredstva: ucheb.-metod. posobie. Minsk: BGMU, 2016. 36 p. (In Russ.).

25. Ivanova L. N. Akvaporiny pochek: struktura, funkcija, reguljacija ISSN 1561-6274. Nefrologija. 2001;5(3):61–66. (In Russ.).

26. Wagner Carsten A. Pendrin-a new target for diuretic therapy? Journal of the American Society of Nephrology (JASN). 2016;27(12):3499– 3501. https://doi.org/10.1681/ASN.2016070720.